{
    "nct_id": "NCT05283720",
    "official_title": "Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma",
    "inclusion_criteria": "* Diagnosis of:\n\n  -- Diffuse large B-cell lymphoma (DLBCL) (de novo or histologically transformed from follicular lymphoma (FL) or nodal marginal zone lymphoma) with histologically confirmed CD20+ disease at most recent representative tumor biopsy pathology report, inclusive of the following according to World Health Organization (WHO) 2016 classification and documented in pathology report:\n  * DLBCL, not otherwise specified (NOS).\n  * High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per WHO 2016 (\"double-hit\" or \"triple-hit\") Note: High-grade B-cell lymphomas NOS or other double- /triple-hit lymphomas (with histologies not consistent with DLBCL) are not eligible.\n  * Follicular lymphoma (FL) Grade 3B. OR\n* FL with histologically confirmed CD20+ Grade 1 to 3a and no evidence of histologic transformation to an aggressive lymphoma at most recent representative tumor biopsy, according to WHO 2016 classification. OR\n* Mantle cell lymphoma (MCL) with histologically confirmed CD20+ disease at most recent representative tumor biopsy according to the WHO 2016 classification with evidence of overexpression of cyclin D1 in association with relevant markers or evidence of t(11;14) assessed by flow cytometry, FISH, or polymerase chain reaction (PCR).\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2, except for Arms 6, 7, and 8 where ECOG performance status must be 0-1.\n* Must have 1 or more measurable disease sites:\n\n  * A positron emission tomography (PET) /computed tomography (CT) scan demonstrating PET-positive lesion(s) AND\n  * At least 1 measurable nodal lesion (long axis > 1.5 cm) or >= 1 measurable extra-nodal lesion (long axis > 1.0 cm) on CT scan or magnetic resonance imaging (MRI).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with epcoritamab or any other bispecific antibody targeting CD3 and CD20.\n* Toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Events (CTCAE, v 5.0), Grade 2 or below, with the exception of alopecia. Other eligibility criteria (e.g., laboratory, cardiac criteria) must also be met.",
    "miscellaneous_criteria": ""
}